Gilead Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GILEAD, and what generic alternatives to GILEAD drugs are available?
GILEAD has thirty approved drugs.
There are eighty-eight US patents protecting GILEAD drugs.
There are two thousand three hundred and twenty-two patent family members on GILEAD drugs in sixty-six countries and three hundred and ninety-seven supplementary protection certificates in nineteen countries.
Summary for Gilead
International Patents: | 2322 |
US Patents: | 88 |
Tradenames: | 24 |
Ingredients: | 24 |
NDAs: | 30 |
Patent Litigation for Gilead: | See patent lawsuits for Gilead |
PTAB Cases with Gilead as patent owner: | See PTAB cases with Gilead as patent owner |
Drugs and US Patents for Gilead
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VITEKTA | elvitegravir | TABLET;ORAL | 203093-001 | Sep 24, 2014 | DISCN | Yes | No | 7,635,704*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Gilead Sciences Inc | BIKTARVY | bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210251-001 | Feb 7, 2018 | RX | Yes | Yes | 9,708,342 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | RE46762*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Gilead | LETAIRIS | ambrisentan | TABLET;ORAL | 022081-002 | Jun 15, 2007 | AB | RX | Yes | Yes | 9,474,752 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | PELLETS;ORAL | 214187-001 | Jun 10, 2021 | RX | Yes | No | 8,618,076*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Gilead
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Gilead Sciences | ATRIPLA | efavirenz; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 021937-001 | Jul 12, 2006 | 5,922,695*PED | ⤷ Try a Trial |
Gilead Sciences Inc | ODEFSEY | emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate | TABLET;ORAL | 208351-001 | Mar 1, 2016 | 5,914,331*PED | ⤷ Try a Trial |
Gilead Sciences Inc | COMPLERA | emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate | TABLET;ORAL | 202123-001 | Aug 10, 2011 | 9,457,036 | ⤷ Try a Trial |
Gilead Sciences Inc | STRIBILD | cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203100-001 | Aug 27, 2012 | 5,977,089*PED | ⤷ Try a Trial |
Gilead | EMTRIVA | emtricitabine | CAPSULE;ORAL | 021500-001 | Jul 2, 2003 | 5,914,331*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GILEAD drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2015-02-09 |
➤ Subscribe | Tablets | 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg | ➤ Subscribe | 2017-05-19 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2010-01-26 |
➤ Subscribe | Tablets | 200 mg/25 mg/300 mg | ➤ Subscribe | 2015-05-20 |
➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2015-12-09 |
➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2010-06-08 |
➤ Subscribe | Tablets | 200 mg/300 mg | ➤ Subscribe | 2008-09-26 |
➤ Subscribe | Tablets | 600 mg/200 mg/300 mg | ➤ Subscribe | 2008-12-29 |
➤ Subscribe | Tablets | 150 mg, 200 mg, and 250 mg | ➤ Subscribe | 2012-05-17 |
➤ Subscribe | Tablets | 150 mg, 150 mg, 200 mg, 300 mg | ➤ Subscribe | 2018-10-04 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2012-07-16 |
International Patents for Gilead Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Taiwan | 201632183 | ⤷ Try a Trial |
Norway | 339223 | ⤷ Try a Trial |
Mexico | 336627 | ⤷ Try a Trial |
Poland | 2870160 | ⤷ Try a Trial |
Austria | 550074 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Gilead Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3808743 | C03808743/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: RILPIVIRIN UND EMTRICITABIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 62155 12.03.2013 |
1663240 | 2015/054 | Ireland | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
2487166 | 122016000104 | Germany | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1061 20151119 |
1419152 | 92008 | Luxembourg | ⤷ Try a Trial | 92008, EXPIRES: 20261128 |
2203462 | PA2014040 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIRUM; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.